Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008

被引:10
作者
Christian, Jennifer B. [1 ]
Bourgeois, Nancy E. [1 ]
Lowe, Kimberly A. [2 ]
机构
[1] GlaxoSmithKline, Worldwide Epidemiol, Durham, NC USA
[2] Exponent Hlth Sci, Bellevue, WA USA
关键词
dyslipidemic agent; high-density lipoprotein cholesterol; National Health and Nutrition Examination Survey; triglycerides; CORONARY-HEART-DISEASE; ESTER TRANSFER PROTEIN; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; ATORVASTATIN; AVERAGE; EVENTS; SIMVASTATIN; PRAVASTATIN; INHIBITION;
D O I
10.2459/JCM.0b013e328349c4e5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The aims of this study were to estimate the prevalence of low high-density lipoprotein cholesterol (HDL-C) in US adults, assess the association between low HDL-C levels and clinical characteristics, and quantify the utilization of dyslipidemic agents as it relates to the distribution of HDL-C. Methods We analyzed a sample of 4129 adults (>20 years) who underwent fasting blood evaluations in the National Health and Nutrition Examination Survey (NHANES) 2005-2008. Sex-specific crude and adjusted logistic models were developed to evaluate the association between individual characteristics and low HDL-C, in which low HDL-C was defined as less than 40 mg/dl for men and less than 50 mg/dl for women. Results Approximately 24% of men and 27% of women had low HDL-C levels. Factors most strongly associated with low HDL-C levels for men included being obese [odds ratio (OR)=3.27, 95% confidence interval (CI): 1.98-5.40], having elevated triglyceride levels (>200 mg/dl: OR=8.17, 95% CI: 5.54-12.03) and having apolipoprotein B levels more than 117 mg/dl (OR=5.99, 95% CI: 2.74-13.13). The same factors were associated with low HDL-C levels among women: being obese (OR=2.89, 95% CI: 1.78-4.71), having elevated triglyceride levels (> 200 mg/dl: OR=13.35, 95% CI: 7.49-23.77) and having apolipoprotein B levels more than 117 mg/dl (OR=5.88, 95% CI: 2.29-15.11). Approximately 82% of men and 79% of women with low HDL-C levels reported not using any dyslipidemic medication. Conclusion Although having low HDL-C was common among US adults, few reported taking a dyslipidemic agent. Our study also confirmed some of the known risk factors associated with low HDL-C levels in the general US population.
引用
收藏
页码:714 / 722
页数:9
相关论文
共 32 条
[1]  
[Anonymous], 2002, JAMA, V288, P2998
[2]  
[Anonymous], 2010, National Health and Nutrition Examination Survey
[3]   High-density lipoprotein function - Recent advances [J].
Ansell, BJ ;
Watson, KE ;
Fogelman, AM ;
Navab, M ;
Fonarow, GC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (10) :1792-1798
[4]   Prevalence of cardiovascular comorbidities and utilization of evidence-based treatment strategies among statin users in a Medicare and commercial health plan [J].
Aronow, Herbert D. ;
Dutro, Michael P. ;
Kuznik, Andreas ;
Cwengros, James .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (01) :205-213
[5]   Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol [J].
Brousseau, ME ;
Schaefer, EJ ;
Wolfe, ML ;
Bloedon, LT ;
Digenio, AG ;
Clark, RW ;
Mancuso, JP ;
Rader, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1505-1515
[6]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[7]   HDL CHOLESTEROL AND OTHER LIPIDS IN CORONARY HEART-DISEASE - COOPERATIVE LIPOPROTEIN PHENOTYPING STUDY [J].
CASTELLI, WP ;
DOYLE, JT ;
GORDON, T ;
HAMES, CG ;
HJORTLAND, MC ;
HULLEY, SB ;
KAGAN, A ;
ZUKEL, WJ .
CIRCULATION, 1977, 55 (05) :767-772
[8]   Prevalence of Severe (500 to 2,000 mg/dl) Hypertriglyceridemia in United States Adults [J].
Christian, Jennifer B. ;
Bourgeois, Nancy ;
Snipes, Rose ;
Lowe, Kimberly A. .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (06) :891-897
[9]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[10]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3